|
1 Indications And Usage Mvasi Is A Vascular Endothelial Growth Factor Inhibitor Indicated For The Treatment Of: Metastatic Colorectal Cancer, In Combination With Intravenous Fluorouracil-Based Chemotherapy For First- Or Second-Line Treatment. ( 1.1 ) Metastatic Colorectal Cancer, In Combination With Fluoropyrimidine-Irinotecan- Or Fluoropyrimidine-Oxaliplatin-Based Chemotherapy For Second-Line Treatment In Patients Who Have Progressed On A First-Line Bevacizumab Product-Containing Regimen. ( 1.1 ) Limitations Of Use : Mvasi Is Not Indicated For Adjuvant Treatment Of Colon Cancer. ( 1.1 ) Unresectable, Locally Advanced, Recurrent Or Metastatic Non-Squamous Non-Small Cell Lung Cancer, In Combination With Carboplatin And Paclitaxel For First-Line Treatment. ( 1.2 ) Recurrent Glioblastoma In Adults. ( 1.3 ) Metastatic Renal Cell Carcinoma In Combination With Interferon-Alfa. ( 1.4 ) Persistent, Recurrent, Or Metastatic Cervical Cancer, In Combination With Paclitaxel And Cisplatin, Or Paclitaxel And Topotecan. ( 1.5 ) 1.1 Metastatic Colorectal Cancer Mvasi, In Combination With Intravenous Fluorouracil-Based Chemotherapy, Is Indicated For The First- Or Second-Line Treatment Of Patients With Metastatic Colorectal Cancer (Mcrc). Mvasi, In Combination With Fluoropyrimidine-Irinotecan- Or Fluoropyrimidine-Oxaliplatin-Based Chemotherapy, Is Indicated For The Second-Line Treatment Of Patients With Mcrc Who Have Progressed On A First-Line Bevacizumab Product-Containing Regimen. Limitations Of Use : Mvasi Is Not Indicated For Adjuvant Treatment Of Colon Cancer [ S Ee Clinical Studies ( 14.2 )] . 1.2 First-Line Non-Squamous Non-Small Cell Lung Cancer Mvasi, In Combination With Carboplatin And Paclitaxel, Is Indicated For The First-Line Treatment Of Patients With Unresectable, Locally Advanced, Recurrent Or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsclc). 1.3 Recurrent Glioblastoma Mvasi Is Indicated For The Treatment Of Recurrent Glioblastoma (Gbm) In Adults. 1.4 Metastatic Renal Cell Carcinoma Mvasi, In Combination With Interferon-Alfa, Is Indicated For The Treatment Of Metastatic Renal Cell Carcinoma (Mrcc). 1.5 Persistent, Recurrent, Or Metastatic Cervical Cancer Mvasi, In Combination With Paclitaxel And Cisplatin Or Paclitaxel And Topotecan, Is Indicated For The Treatment Of Patients With Persistent, Recurrent, Or Metastatic Cervical Cancer.
|